A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
A phase 1/2 trial of MRG006A in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.
Overview
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07093970 by Lepu Biopharma Co., Ltd., with 343 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: MRG006A.
Similar pages
not linked directly; found by shared links- TrialA Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
Shares Lepu Biopharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Shares Lepu Biopharma and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.